AI Engines For more Details: Perplexity Kagi Labs You
Antidepressant Effects: Viloxazine hydrochloride acts primarily as a selective norepinephrine reuptake inhibitor (NRI). By inhibiting the reuptake of norepinephrine, it increases the levels of this neurotransmitter in the brain, which is thought to alleviate symptoms of depression. Its antidepressant effects are believed to be mediated by modulation of neurotransmitter activity in brain regions involved in mood regulation.
Treatment of Depression: Viloxazine hydrochloride is indicated for the treatment of major depressive disorder (MDD) in adults. It may help improve mood, reduce feelings of sadness and hopelessness, and alleviate other symptoms associated with depression, such as fatigue, sleep disturbances, and changes in appetite or weight.
Management of ADHD: Viloxazine hydrochloride is also approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. It may help reduce symptoms of inattention, hyperactivity, and impulsivity, improving focus, concentration, and behavioral control in individuals with ADHD.
Noradrenergic Modulation: As an NRI, viloxazine hydrochloride primarily targets the noradrenergic system in the brain. By enhancing noradrenergic neurotransmission, it may exert stimulant-like effects on cognitive function and arousal, contributing to its therapeutic efficacy in ADHD.
Mechanism of Action: Viloxazine hydrochloride inhibits the presynaptic reuptake of norepinephrine into nerve terminals, leading to increased extracellular levels of this neurotransmitter. This mechanism is believed to enhance noradrenergic signaling and neurotransmission, which may be beneficial in the treatment of depression and ADHD.
Side Effects: Common side effects associated with viloxazine hydrochloride may include gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), headache, dizziness, insomnia, dry mouth, and changes in appetite or weight. Less commonly, it may cause cardiovascular effects such as increased heart rate or blood pressure.
Safety and Tolerability: Viloxazine hydrochloride is generally well-tolerated when used at therapeutic doses. However, it may interact with other medications or substances, and caution is advised in individuals with certain medical conditions, such as cardiovascular disease, hypertension, or glaucoma. Dosage adjustments or monitoring may be necessary in these populations.
Regulatory Status: Viloxazine hydrochloride is available by prescription in some countries for the treatment of depression and ADHD. It is typically administered orally in the form of tablets or capsules and should be taken as directed by a healthcare professional.
Clinical Considerations: Before initiating treatment with viloxazine hydrochloride, healthcare providers should conduct a thorough evaluation of the patient's medical history, psychiatric symptoms, and medication regimen. Close monitoring may be required during treatment to assess therapeutic response and monitor for adverse effects or potential drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.9 | -2 |
| ADHD | 4.3 | 0.6 | 6.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 1.9 | 0.47 |
| Allergies | 5.5 | 2.7 | 1.04 |
| Allergy to milk products | 1.5 | 1.6 | -0.07 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 4.6 | 5.2 | -0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.7 | 2.71 |
| Ankylosing spondylitis | 3.5 | 1.2 | 1.92 |
| Anorexia Nervosa | 1.6 | 2.3 | -0.44 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 4.5 | 2.5 | 0.8 |
| Atherosclerosis | 1.6 | 1.6 | 0 |
| Atrial fibrillation | 2.9 | 1.7 | 0.71 |
| Autism | 7.3 | 7.6 | -0.04 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.9 | 2.1 | -1.33 |
| Carcinoma | 4.2 | 2.6 | 0.62 |
| Celiac Disease | 1.7 | 3.7 | -1.18 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 3.5 | 4 | -0.14 |
| Chronic Kidney Disease | 4.1 | 1.9 | 1.16 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 1.7 | -0.55 |
| Chronic Urticaria (Hives) | 1.5 | 0.3 | 4 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.4 | 1.6 | 1.13 |
| Colorectal Cancer | 6.7 | 2 | 2.35 |
| Constipation | 1.9 | 0.7 | 1.71 |
| Coronary artery disease | 1.6 | 1.5 | 0.07 |
| COVID-19 | 8 | 7.5 | 0.07 |
| Crohn's Disease | 6.1 | 4.5 | 0.36 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 0.7 | 1.7 | -1.43 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 8.6 | 7.4 | 0.16 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.3 | 0.31 |
| Endometriosis | 2.7 | 1.9 | 0.42 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.5 | 1.6 | 0.56 |
| erectile dysfunction | 1.5 | 0.3 | 4 |
| Fibromyalgia | 2.7 | 0.9 | 2 |
| Functional constipation / chronic idiopathic constipation | 4.7 | 3.4 | 0.38 |
| gallstone disease (gsd) | 2.7 | 1.2 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 1 | 0.2 |
| Generalized anxiety disorder | 2.1 | 2.4 | -0.14 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2 | 0.6 | 2.33 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.6 | 0.7 | -0.17 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 3.5 | 1.6 | 1.19 |
| Heart Failure | 3 | 1.4 | 1.14 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.2 | 2 |
| hyperglycemia | 1.8 | 1.5 | 0.2 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.5 | 4.4 | 0.02 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 2.7 | 0.4 | 5.75 |
| IgA nephropathy (IgAN) | 1.9 | 2.7 | -0.42 |
| Inflammatory Bowel Disease | 5.8 | 6.2 | -0.07 |
| Insomnia | 1.7 | 2.5 | -0.47 |
| Intelligence | 0.6 | 0.1 | 5 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 6.3 | 4.5 | 0.4 |
| ischemic stroke | 3 | 1.4 | 1.14 |
| Liver Cirrhosis | 6.1 | 4.2 | 0.45 |
| Long COVID | 5.2 | 6.5 | -0.25 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.1 | 1.3 | -0.18 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.6 | 0.67 |
| ME/CFS with IBS | 0.7 | 1.6 | -1.29 |
| ME/CFS without IBS | 0.9 | 1.9 | -1.11 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.9 | 0.7 | 1.71 |
| Metabolic Syndrome | 6.2 | 6.8 | -0.1 |
| Mood Disorders | 8.1 | 5.9 | 0.37 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.8 | 3.8 | 0.53 |
| Multiple system atrophy (MSA) | 0.9 | 0.7 | 0.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.9 | -8.67 |
| Neuropathy (all types) | 0.8 | 2.5 | -2.13 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.9 | 4 | 0.23 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 9.6 | 6.6 | 0.45 |
| obsessive-compulsive disorder | 4 | 2.8 | 0.43 |
| Osteoarthritis | 1.6 | 1.3 | 0.23 |
| Osteoporosis | 2.5 | 1.5 | 0.67 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 6.7 | 4.3 | 0.56 |
| Polycystic ovary syndrome | 4.6 | 2.6 | 0.77 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.2 | 1.6 | 0.38 |
| Psoriasis | 2.9 | 1.8 | 0.61 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.7 | 3.2 | 1.09 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 5.5 | 2.9 | 0.9 |
| scoliosis | 0.1 | 0.8 | -7 |
| Sjögren syndrome | 2.5 | 2.1 | 0.19 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.7 | 1.14 |
| Stress / posttraumatic stress disorder | 2.9 | 2.2 | 0.32 |
| Systemic Lupus Erythematosus | 3.1 | 1.8 | 0.72 |
| Tic Disorder | 1.3 | 1.2 | 0.08 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 3.3 | 4.1 | -0.24 |
| Type 2 Diabetes | 7 | 6 | 0.17 |
| Ulcerative colitis | 4.3 | 4.5 | -0.05 |
| Unhealthy Ageing | 3.6 | 1.7 | 1.12 |
| Vitiligo | 1.9 | 1 | 0.9 |
